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Abstract
Increasing antimicrobial resistance in nontyphoidal Salmonella (NTS) species complicates the use of antibiotics if indicated. We investi-
gated the impact of antimicrobial resistance on clinical outcomes and discussed how to use antibiotics rationally. Hospitalized children
in 2005–2006 with stool cultures positive for NTS were identiﬁed. The clinical and microbiological features were retrospectively
reviewed. A total of 683 children were included [371 (54.3%) male; 89.5% <5 years of age]. Antibiotics were given to 56.5% of the
patients; third-generation cephalosporin was the most commonly used drug class. Cases receiving antibiotics that were inactive in vitro
did not have more complications than those receiving antibiotics active in vitro. Complications occurred in 7.9% of the patients, with
bacteraemia being the most common (57.4%). Compared to the others, patients with longer febrile duration and higher C-reactive pro-
tein (CRP) levels (CRP ‡100 mg/L) were more frequently put on empirical antimicrobial therapy and had more complications. These
patients usually had shorter hospitalization and duration of fever if antimicrobial agents that can reach high tissue concentrations in the
intestinal mucosa were administered, such as ﬂuoroquinolone or ceftriaxone. It is concluded that adequate antibiotics may be clinically
beneﬁcial to a subset of patients with high CRP and longer duration of fever among children with NTS enteritis. To prevent the induc-
tion of antibiotic resistance from this therapy, we suggested a short course (3–5 days) of intravenous ceftriaxone for such patients,
which would lead to a faster clinical recovery.
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Introduction
Nontyphoidal Salmonella (NTS) infection is still a serious
threat to global public health [1–4]. Most NTS infections
result in mild-to-moderate enteritis, although systemic
infections, including bacteraemia and meningitis, may occur,
especially in infants and immunocompromised hosts [5,6].
Antimicrobial therapy is not recommended for routine treat-
ment of nontyphoidal salmonellosis [7,8]; however, effective
antibiotic treatment is essential if NTS infection spreads
beyond the intestine or if NTS enteritis occurs in patients
with low immunity (e.g. infants younger than 3 months of age
and patients with immunosuppressive illnesses) [9]. Anti-
microbial therapy may also be considered in severely ill
immunocompetent adult patients, such as those with severe
diarrhoea (more than nine or 10 stools per day), high fever,
or those needing hospital admission [10].
Ampicillin, chloramphenicol and trimethoprim-sulphameth-
oxazole were the drugs of choice in the treatment of inva-
sive salmonellosis before the 1980s but, during the past two
decades, resistance to these agents has increased in many
areas of the world [11–13]. Expanded-spectrum cephalospo-
rins and ﬂuoroquinolones are recommended as alternatives
in such a setting because of their favourable pharmacokinetic
properties and low prevalence of resistance [13–16]. How-
ever, increasing numbers of cases of ciproﬂoxacin- or ceftri-
axone-resistant Salmonella have been reported subsequent to
the 1990s [13,17].
Despite the increasing incidence of antimicrobial-resistant
NTS infections, little is known about the impact of antibiotic
resistance on patient outcome. In the present study, we ana-
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lyzed the clinical and microbiological features of hospitalized
children with nontyphoidal salmonellosis. We used the data
to reassess indications for parenteral antimicrobial therapy in
immunocompetent children with NTS enteric infection.
Materials and Methods
From January 2005 to December 2006, hospitalized patients
aged younger than 18 years of age with stool culture positive
for NTS were identiﬁed from the records of the clinical
microbiology laboratory at Chang Gung Children’s Hospital.
Demographic features, clinical manifestations, laboratory ﬁnd-
ings, microbiological results, antimicrobial susceptibility,
treatment regimens and clinical outcomes were retrospec-
tively reviewed and analyzed.
All decisions regarding antibiotic therapy were made by
the attending physicians who took care of the patients. The
initial antibiotic regimen was administered after blood and
stool cultures had been taken. Deﬁnitive antimicrobial
therapy was then given after culture results were obtained.
The antibiotic regimen was considered as concordant treat-
ment if it contained at least one drug active in vitro against
the subsequent Salmonella isolate. Discordant antimicrobial
therapy comprised the use of a regimen without any appro-
priate drug to which the causative organism was sensitive.
Antibiotics that can achieve high tissue concentration, such
as third-generation cephalosporins or ﬂuoroquinolones, were
considered as ‘adequate’ agents.
All isolates were identiﬁed by standard methods [18].
Salmonella serogroup was determined by the slide agglutina-
tion method using antisera speciﬁc to O antigen (Difco Labo-
ratories, Detroit, MI, USA). (Group C1) Salmonella negative
for Vi antigen and citrate-negative were deﬁned as the
serogroup Salmonella choleraesuis. Salmonella of group D1 that
were Vi antigen-negative were designated serogroup D1.
Salmonella typhi/paratyphi strains were excluded by detection
of Vi-speciﬁc antigen. The antimicrobial susceptibilities of
the isolates were investigated by a standard disc-diffusion
method [19]. The antimicrobial agents examined included
ampicillin, ﬂomoxef, ceﬁxime, ceftriaxone, imipenem, chl-
oramphenicol, ciproﬂoxacin and trimethoprim/sulphameth-
oxazole. Susceptibility and resistance were deﬁned according
to the criteria suggested by the CLSI [19].
Data were analyzed using SPSS, version 11.0 (SPSS inc.,
Chicago, IL, USA). Student’s t-test was used to analyze numer-
ical data. If the data were not normally distributed, the Mann–
Whitney U-test was used to compare nonparametric data. A
chi-square test or Fisher’s exact test was used to analyze cate-
gorical data. p <0.05 was considered statistically signiﬁcant.
Results
Demographics and clinical characteristics
A total of 683 children were identiﬁed during the study per-
iod. Three hundred and seventy-one (54.3%) patients were
male and 611 (89.5%) were aged under 5 years, with a med-
ian age of 18 months. Thirty-four patients (5.0%) had under-
lying conditions [febrile seizures in ten, prematurity in ﬁve,
asthma in ﬁve, thalassemia trait in three, glucose-6-phosphate
dehydrogenase deﬁciency in three, congenital heart disease
in two, and others (including cerebral palsy, gastroesophageal
reﬂux disorder, vesicoureteral reﬂux, craniosynostosis and
lung anomaly with cystic adenomatoid malformation) in six];
no abnormalities in the gastrointestinal tract and no life-
threatening diseases or immunodeﬁciency conditions were
recorded. The majority of the infections (416, 60.9%)
occurred between June and October.
Fever and diarrhoea were the most common initial pre-
sentations. Bloody and mucoid diarrhoea was found in 39.3%
(262/667 and 28.0% (187/667) of the patients, respectively.
Blood cultures were obtained in 93.4% (638/683) of the
patients; 4.9% (31/638) showed NTS bacteraemia. Follow-up
information for at least 6 months after cessation of antibiotic
therapy was obtained from medical records. Neither focal
suppurative complications, nor clinically recurrent diseases
were found in these patients during the follow-up period.
Complications were found during or after antimicrobial ther-
apy in 7.9% (54/683) of the patients overall, including bactera-
emia (31 cases), toxic megacolon (20 cases), bowel
perforation (two cases) and acute appendicitis (one case). The
patients with bowel perforation and appendicitis received sur-
gical intervention. No fatality occurred in this cohort of
patients. The only parameter among demographics and clinical
manifestations associated with complications was C-reactive
protein (CRP), especially a level ‡100 mg/L (OR 2.08, 95%
CI 1.17–3.72, p 0.013; multivariate analysis: OR 1.85, 95%
CI 1.01–3.46, p 0.047) (data of other parameters not shown).
Serogroup distribution and antimicrobial susceptibility
The distribution of serogroups and patterns of antimicrobial
susceptibility of the NTS isolates are shown in Table 1.
Salmonella serogroup B was the most common, accounting
for 50.1% (342/683) overall, followed by serogroups D1, C2,
and C1. Of these isolates, antimicrobial resistance rates to
conventional antibiotics (43.9% to ampicillin, 44.8% to chl-
oramphenicol and 27.1% to trimethoprim/sulphamethoxa-
zole) were much higher than those to other drugs (0% to
ciproﬂoxacin and to imipenem, 4.1% to ceftriaxone, 3.3% to
ﬂomoxef and 4.4% to ceﬁxime). For the third-generation
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cephalosporins, there was resistance to ceftriaxone in 28/
676 (4.1%,) of isolates and resistance to ceﬁxime in 29/663
(4.4%) isolates. Most of these isolates belonged to sero-
groups B and D1. In 31 cases with Salmonella bacteraemia,
serogroup B accounted for 15 (48.4%), followed by sero-
groups C2 (22.6%), D1 (19.4%) and C1 (9.7%).
Antimicrobial therapy
Fifty-seven percent (386/683) of patients received antimicro-
bial therapy; the most commonly used empirical regimes
were third-generation cephalosporins (46.6%, 180/386) and
ampicillin (39.9%, 154/386), alone or with gentamicin. The
most common regimens used for deﬁnitive antimicrobial
therapy were also third-generation cephalosporins (54.9%,
212/386) and ampicillin (32.6%, 126/386), alone or with
gentamicin. The rates of initial and deﬁnitive concordant anti-
biotic usage were 75.1% (290/386) and 80.6% (311/386),
respectively. In our series, the average duration of anti-
microbial therapy was 4.7 ± 2.4 days (range 1–16 days).
We analyzed the clinical features of patients with or with-
out antimicrobial therapy (Table 2). Cases with fever were
more frequently put on antimicrobials than those without.
The duration of fever and diarrhoea was longer in patients
treated with antimicrobials than those not treated. CRP lev-
els were signiﬁcantly higher and white blood cell counts
were borderline higher in patients who received antibiotics
than in those who did not. More cases of bacteraemia were
identiﬁed among patients who were given empirical antibiot-
ics on admission (7.0%, 27/386 vs. 1.3%, 4/297, p <0.001).
Impact of antimicrobial resistance on clinical outcomes
To assess the impact of antimicrobial resistance on the
clinical course of nontyphoidal salmonellosis, we compared
outcomes between cases with and without concordant initial
antimicrobial therapy in the antibiotic-treated group
(Table 3). Patients receiving antibiotics inactive in vitro did
not have more severe illnesses than those receiving anti-
biotics active in vitro, in terms of duration of fever, length of
hospitalization and the occurrence of complications such as
bacteraemia or toxic megacolon.
Comparison of disease severity of selected patients with
and without adequate antimicrobial therapy
Our data showed that patients with a longer duration of
fever before admission and higher CRP had more severe ill-
nesse and were put on antibiotics. To investigate whether
adequate antimicrobial therapy affected the clinical course of
these patients, we compared disease severity among selected
patients with and without adequate antimicrobial treatment.
Patients were selected for comparison if they suffered from
fever for more than 2 days prior to admission and had an
initial CRP ‡100 mg/L. Table 3 shows the results of this
comparison. We found that total febrile duration and febrile
duration after antimicrobial therapy was shorter in the cases
with adequate antimicrobial therapy compared to those with-
out. (mean: 1.8 ± 1.7 days vs. 2.6 ± 2.0 days)
Cases with adequate antimicrobial therapy had a border-
line shorter duration of hospitalization compared to those
without. There was no signiﬁcant difference between the
groups, in terms of the duration of diarrhoea and occurrence
of complications.
Discussion
Patients with invasive salmonellosis or severe enteritis
require antimicrobial therapy. However, the difﬁculty in
differentiating between severe and self-limited enteritis in
clinical practice complicates the issue of antimicrobial ther-
apy [12,20,21]. Careful identiﬁcation of at-risk patients and
TABLE 1. Serogroup distribution and antimicrobial resistance of nontyphoidal Salmonella isolates from stool
Antibiotics
Serogroup
Total
(N = 676)a
n (%)
Group B
(N = 342)
n (%)
Group C1
(N = 54)
n (%)
S. choleraesuis
(N = 3)
n (%)
Group C2
(N = 85)
n (%)
Group D1
(N = 184)
n (%)
Group E
(N = 6)
n (%)
Group G
(N = 2)
n (%)
Ampicillin 237/342 (69.3) 9/54 (16.7) 1/3 (33.3) 39/85 (45.9) 9/184 (4.9) 2/6 (33.3) 0/2 297/676 (43.9)
Chloramphenicol 248/342 (72.5) 8/54 (14.8) 1/3 (33.3) 39/85 (45.9) 5/184 (2.7) 1/6 (16.7) 1/2 (50.0) 303/676 (44.8)
TMP/SMX 125/342 (36.5) 16/54 (29.6) 1/3 (33.3) 37/85 (43.5) 3/184 (1.6) 1/6 (16.7) 0/2 183/676 (27.1)
Ciproﬂoxacin 0/342 0/54 0/3 0/85 0/184 0/6 0/2 0
Ceftriaxone 16/342 (4.7) 1/54 (1.9) 1/3 (33.3) 3/85 (3.5) 7/184 (3.8) 0/6 0/2 28/676 (4.1)
Flomoxef 12/342 (3.5) 1/54 (1.9) 1/3 (33.3) 3/85 (3.5) 5/184 (2.7) 0/6 0/2 22/676 (3.3)
Ceﬁxime 17/334 (5.1) 1/54 (1.9) 1/3 (33.3) 3/83 (3.6) 7/181 (3.9) 0/6 0/2 29/663 (4.4)
Imipenem 0/342 0/54 0/3 0/85 0/184 0/6 0/2 0
TMP/SMX, trimethoprim/sulphamethoxazole.
aA total of 683 children had stool culture positive for nontyphoidal Salmonella (NTS). However, the results of serogrouping distribution were not available in 7 of them. Thus,
only 676 cases are shown in Table 1.
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the early initiation of effective antibiotics are crucial in the
treatment of nontyphoidal salmonellosis. In the present
study, patients with a longer duration of fever prior to
admission and higher CRP values were frequently put on
empirical antimicrobial therapy and these patients indeed had
some characteristics of more severe illness, including dura-
tion of fever, diarrhoea and bacteraemia. In the univariate
and multivariate analyses, higher CRP (‡100 mg/L) was also a
signiﬁcant risk factor for an eventful outcome. Despite having
a longer total duration of fever and diarrhoea and a higher
rate of complications, patients with higher CRP (especially
‡100 mg/L) and a longer febrile duration prior to admission
(especially ‡2 days) may beneﬁt from the administration of
antibiotics that can reach high tissue concentrations in the
intestinal mucosa, such as third-generation cephalosporins or
ﬂuoroquinolones, as shown by the shortened duration of
fever or hospitalization in the present study. Thus, CRP
‡100 mg/L and febrile duration ‡2 days prior to treatment
appear to be simple and objective indicators of patients with
severe NTS enteritis who need antimicrobial therapy.
Although a previous meta-analysis of 12 trials involving 778
healthy individuals with NTS enteritis found no signiﬁcant
beneﬁt from antimicrobial therapy on the length of illness
[22], most cases in these studies were not severely ill, and
most received chloramphenicol or sulphamethoxazole-tri-
methoprim as empirical antibiotics. On the basis of the result
obtained in the present study, we speculate that the use of
antibiotics that achieve higher tissue concentrations, such as
the ﬂuoroquinolones and expanded-spectrum cephalosporins,
may produce different conclusions.
In our series, the resistance rates of nontyphoidal Salmo-
nella to conventional antibiotics, such as ampicillin, chloram-
phenicol and sulphamethoxazole-trimethoprim, were 27–45%.
These resistance rates are similar to those reported in a
previous study from the same institution in 2004 [12], except
that ceftriaxone resistance (4.1%), was much higher than the
TABLE 2. Demographics, clinical manifestations, and laboratory ﬁndings of 683 paediatric cases with and without antimicro-
bial therapy
Characteristics
Total
N = 683
n (%)
Cases with
antimicrobial therapy
N = 386
n (%)
Cases without
antimicrobial therapy
N = 297 n (%) p-value
Age (months)
Median (range) 18.0 (1.0–210.0) 20.0 (1.0–210.0) 16.0 (1.0–153.0) 0.121
<3 months 21 13 8
3 months to 1 year 188 96 92
>1 year 474 277 197
Sex (male/female) 371/312 210/176 161/136 0.959
Fever 641 (93.9) 374 (96.9) 267 (89.9) <0.001
Before admission (days)
Median (range) 2.0 (0.0–28.0) 2.0 (0.0–28.0) 2.0 (0.0–14.0) 0.025
After antibiotics treatment (days)
Median (range) 2.0 (0.0–10.0) 2.0 (0.0–10.0) 0.0 (0.0–4.0) <0.001
Total febrile duration (days)
Median (range) 4.0 (0.0–32.0) 5.0 (0.0–32.0) 3.0 (0.0–20.0) <0.001
Diarrhoea 667 (97.7) 377 (97.7) 290 (97.6) 1.000
Duration (days)
Median (range) 6.0 (0.0–35.0) 7.0 (0.0–35.0) 6.0 (0.0–20.0) <0.001
Bloody/mucous (proportion) 262/187 125/100 137/87 0.228
Nausea/vomiting 235 (34.4) 137 (35.5) 98 (33.0) 0.496
WBC (/mm3)
Mean ± SD 10505.2 ± 4557.0 10794.0 ± 5044.8 10125.7 ± 3798.0 0.058
Range 1400–39100 1400–39100 3300–22800
<5000 46 31 15
5000–15 000 535 285 250
>15 000 97 70 27
Platelet (·103/mm3)
Mean ± SD 281.2 ± 96.7 283.6 ± 95.7 278.0 ± 98.0 0.459
Range 26.0–762.0 107.0–615.0 26.0–762.0
CRP (mg/L)
Median 50.3 70.8 34.7 <0.001
Range 0.3–442.8 0.7–442.8 0.3–386.3
<10 88 36 52
10–40 195 81 114
>40 388 263 125
Complicationsa
All complications 48 (12.4) 6 (2.0) <0.001
Complications excluding bacteraemia 21 (5.4) 2 (0.7) <0.001
Bacteraemia 27 (7.0) 4 (1.3) <0.001
SD, standard deviation; WBC, white blood cell; CRP, C-reactive protein.
aNontyphoidal Salmonella infectious complications include bacteraemia (31), toxic megacolon (20), bowel perforation (2) and acute appendicitis (1).
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1.5% reported previously [12]. Increasing resistance to
expanded-spectrum cephalosporins could be caused by indis-
criminate use of antibiotics in animal feed, which might have
facilitated the selection and spread of expanded-spectrum
cephalosporin-resistant Salmonella [20,23]. High resistance
rates to ﬂuoroquinolones for invasive S. choleraesuis strains,
which have been previously reported in Taiwan, were not
found in this study (0%, 0/3) [12,17,20].
One concern regarding antimicrobial therapy is that,
despite its clinical efﬁcacy, ﬂuoroquinolone or expanded-
spectrum cephalosporins may prolong the duration of Salmo-
nella excretion after clinical recovery. This situation was
found in the pre-ﬂuoroquinolone era when other antibiotics
such as chloramphenicol or sulphamethoxazole-trimethoprim
were used [7,24]. Salmonella species are known to persist
within the reticuloendothelial system and survive and repli-
cate within phagocytes [25]. Possible causes for the ineffec-
tiveness of these antibiotics to eradicate Salmonella include
the failure of these antibiotics to reach an adequate concen-
tration and/or the loss of antimicrobial activity in the phago-
somes [26]. Animal studies showed that ceftriaxone is
effective in the intracellular environment of macrophages
[27]. In addition, these agents, including ﬂuoroquinolones,
reach high concentrations in the intestinal mucosa and
gallbladder, and therefore can effectively kill Salmonella that
usually reside in these environments [27,28]. Thus, antimi-
crobial therapy with these newer agents may be effective in
preventing or suppressing the excretion of Salmonella.
Another concern is whether antimicrobial resistance may
affect treatment outcomes of nontyphoidal salmonellosis.
Although previous studies have identiﬁed an association
between drug resistance and increased rates of illness and
death [20,21], we found that patients receiving antibiotics inac-
tive in vitro did not have more severe illnesses than those who
received active antibiotics. The cause for such a discrepancy is
unclear. One possible explanation is that some patients who
actually did not need antimicrobial therapy were treated with
antibiotics and the inclusion of such patients may have biased
the data analysis in the present study. Nevertheless, in order
to suppress the load of Salmonella in the intestinal tract and
to simultaneously prevent the possible induction of antibiotic
resistance, a short course (3–5 days) of an adequate antibiotic
such as ceftriaxone is suggested in the treatment of severe
NTS gastroenteritis. Antibiotics should be discontinued
as soon as possible when the patient’s clinical condition
improves.
The major limitation of the present study is that the bene-
ﬁt of adequate antimicrobial therapy for NTS infection was
TABLE 3. Comparison of disease severity and complications in 386 paediatric cases receiving antimicrobial treatment with
and without concordant therapy, and selected patientsa with and without adequate antimicrobial therapy
Characteristics
Total
N = 386
Selected patients
N = 142
Cases with initial
concordant
antimicrobial therapyb
N = 290
n (%)
Cases with initial
discordant
antimicrobial therapy
N = 96
n (%) p-value
Cases with initial
adequate antimicrobial
therapyc
N = 74
n (%)
Cases without initial
adequate
antimicrobial herapy
N = 68
n (%) p-value
Age (months)
Median (range) 21.0 (1.0–210.0) 19.0 (1.0–125.0) 0.349 27.5 (2.0–137.0) 26.0 (2.0–175.0) 0.969
Hospitalization (days)
Mean ± SD 6.2 ± 2.7 6.1 ± 2.6 0.709 5.4 ± 2.6 6.2 ± 2.6 0.051
Fever 280 (96.6) 94 (97.9) 0.738
Before admission (days)
Median (range) 2.0 (0.0–28.0) 3.0 (0.0–17.0) 0.292
After antibiotics treatment (days)
Median (range) 2.0 (0.0–10.0) 2.0 (0.0–8.0) 0.660 2.0 (0.0–9.0) 2.0 (0.0–8.0) 0.022
Total febrile duration (days)
Mean ± SD 5.4 ± 3.5 5.7 ± 3.3 0.462 5.5 ± 2.4 6.8 ± 3.2 0.008
Diarrhoea 285 (98.3) 92 (95.8) 0.235 73 (98.6) 66 (97.1) 0.607
After antibiotic treatment (days)
Median (range) 4.0 (0.0–14.0) 4.0 (0.0–14.0) 0.252 4.0 (0.0–14.0) 5.0 (0.0–11.0) 0.103
Duration (days)
Mean ± SD 7.1 ± 3.5 7.8 ± 5.0 0.120 6.8 ± 3.6 7.9 ± 3.3 0.076
NTS infectious complicationsd
All complications 36 (12.4) 9 (9.4) 0.469 9 (12.2) 9 (13.2) 0.848
Complications excluding bacteraemia 15 (5.2) 3 (3.1) 0.579 5 (6.8) 4 (5.9) 1.000
Bacteraemia 21 (7.2) 6 (6.3) 1.000 4 (5.4) 5 (7.4) 0.740
SD, standard deviation.
aSelected patients = patients who suffered from fever ‡2 days prior to admission and had an initial C-reactive protein ‡100 mg/L.
b‘Concordant’ initial antimicrobial therapy = antibiotic regimen which contained at least one drug active in vitro against the Salmonella isolate; ‘discordant’ initial antimicrobial
therapy = antibiotic regimen which included the use of a regimen without any appropriate drug or a drug to which the causative organism was resistant.
cAdequate antimicrobial therapy = antibiotics which can achieve high tissue concentration such as third-generation cephalosporin or ﬂuoroquinolone.
dNontyphoidal Salmonella infectious complications include bacteraemia (31), toxic megacolon (20), bowel perforation (2) and acute appendicitis (1).
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primarily based on clinical observations, such as the shorten-
ing of hospitalization or febrile duration. Quantitative analysis
of the amount and duration of NTS faecal shedding would
give us more objective information on the impact of antimi-
crobial therapy for NTS infection, especially on the appropri-
ate duration of treatment.
In summary, we found that patients with a high CRP and
longer duration of fever before admission may be considered
as having ‘severe NTS enteritis’ and these patients appear to
beneﬁt clinically from antibiotic treatment. A short course of
an effective antibiotic, such as ceftriaxone, is recommended
in such a setting. A large prospective, randomized study may
be needed to evaluate this issue in the future.
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